市場調査レポート

カナダの糖尿病市場レポートと今後の見通し(2011〜2016年)

Canada Diabetes Market Report & Forecast 2011-2016

発行 IMARC Services Pvt. Ltd. 商品コード 195734
出版日 ページ情報 英文 38 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
カナダの糖尿病市場レポートと今後の見通し(2011〜2016年) Canada Diabetes Market Report & Forecast 2011-2016
出版日: 2011年05月15日 ページ情報: 英文 38 Pages

当商品の販売は、2016年06月08日を持ちまして終了しました。

概要

当レポートでは、カナダにおける糖尿病市場について、市場動向、治療の構造、競合構造、2016年までの市場予測などをまとめ、概略以下の構成でお届けします。

第1章 エグゼクティブサマリー

第2章 カナダの糖尿病疫学

  • 総患者数
  • 性別患者数
  • 年齢層別患者数

第3章 カナダの糖尿病市場動向

  • 糖尿病市場
    • 現在までの動向:2005-2010年
    • 市場予測:2011-2016年
  • インスリン市場
    • 現在までの動向:2005-2010年
      • 種類別市場
      • 分子別市場
      • 主な企業
      • 主な薬剤
    • 市場予測:2011-2016年
  • 経口抗糖尿病薬
    • 現在までの動向:2005-2010年
      • 種類別市場
      • 主な企業
      • 主な薬剤
    • 市場予測:2011-2016年

図表

目次
Product Code: SRPH0511B

Abstract

IMARC' s new report “Canada Diabetes Market Report & Forecast 2011-2016” provides an analytical and statistical insight into the Canadian diabetes market. The report provides both current and future trends in the prevalence and demographical breakup of diabetes in Canada. The report has segmented the Canada diabetes market into two segments - Insulin and the Oral Antidiabetics market. For each of the aforementioned categories, the report provides historical and future market sales of key classes, key companies, key drugs and key molecules. The research study serves as an exceptional tool to understand the market trends, therapeutic structure, competitive structure and the outlook of the Canadian diabetes market till 2016. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Canadian diabetes market in some form or the other.

Key Questions Answered in this Report:

  • What is the size and demographical breakup of the diabetes population in Canada?
  • How has the diabetes market behaved since 2005 and what are the expected trends till 2016?
  • What has been the historical performance of the Canadian Insulin market during 2005-2010 and its outlook till 2016?
  • What has been the performance of top classes, top players, top molecules and top drugs in the Insulin market during 2005-2010?
  • What has been the historical performance of the Oral Antidiabetics market during 2005-2010 and its outlook till 2016?
  • What has been the performance of top classes, top players, top molecules and top drugs in the Oral Antidiabetics market during 2005-2010?

Why should you buy this report?

  • Gain a deeper understanding about the prevalence of diabetes in Canada and identify your potential patient pool.
  • Analyze the historical, current and future trends in the Insulin and Oral Antidiabetic markets and identify potential classes, drugs, partners and competitors for market entry and expansion plans.
  • Develop Investment strategies by identifying companies that have been the biggest winners and losers in the Canadian Insulin and Oral Antidiabetic markets.
  • Gain an insight into future market events such as biosimilars and new product launches.

Classes Covered: Fast acting Insulin, Long acting Insulin, Intermediate and Fast acting Insulin, Intermediate acting Insulin, Biguanides, Glitazone and Biguanide Combinations, Biguanide and Sulphonylurea Combinations, Glinides, Sulphonylureas, Glitazones, DPP-IV Inhibitors, Glp-1 Agonists, Alpha-Glucosidase Inhibitors, DPP-IV Inhibitor and Biguanide Combinations, DPP-IV Inhibitor and Glitazone Combinations, Glitazone and Sulphonylurea Combinations, SGLT Inhibitors, SGLT Inhibitor and Biguanide Combinations, PTP1B Inhibitors and all other Oral Antidiabetic classes.

Information Sources: Information has been sourced from both primary and secondary sources:

  • Primary sources include industry surveys and face to face/telephone interviews with physicians and industry experts.
  • Secondary sources include proprietary databases and search engines. These sources include company websites and reports, books, trade journals, magazines, white papers, Industry Portals, government sources and access to more than 4000 paid databases.

Forecasting Methodology: IMARC generates its product and market forecasts utilizing its extensive database of macroeconomic and sector specific data. The initial baseline forecast is generated with the most recent market data. After an initial baseline forecast, all future macroeconomic and sector specific events and assumptions are taken into account to generate the final forecast.

Table of Contents

1. Executive Summary

2. Epidemiology

  • 2.1. Total Diabetes Patients
  • 2.2. Patients by Gender
  • 2.3. Patients by Age Group

3 Market Dynamics

  • 3.1. Diabetes Market
    • 3.1.1. Current Trends (2005-2010)
    • 3.1.2. Market Forecast (2011-2016)
  • 3.2. Insulin Market
    • 3.2.1. Current Trends (2005-2010)
      • 3.2.1.1. Market by Class
      • 3.2.1.2. Market by Molecule
      • 3.2.1.3. Top Players
      • 3.2.1.4. Top Drugs
    • 3.2.2. Market Forecast (2011-2016)
  • 3.3. Oral Antidiabetics
    • 3.3.1. Current Trends (2005-2010)
      • 3.3.1.1. Market by Class
      • 3.3.1.2. Top Players
      • 3.3.1.3. Top Drugs
    • 3.3.2. Market Forecast (2011-2016)

List of Figures:

  • Figure 2-1: Canada - Number of Diabetes Patients* (in 000' s), 2010, 2015, 2020, 2025 & 2030
  • Figure 2-2: Canada - Breakup of Diabetes Patients by Gender* (in 000' s), 2010, 2015, 2020, 2025 & 2030
  • Figure 2-3: Canada - Breakup of Diabetes Patients by Gender* (in %) 2010, 2015, 2020, 2025 & 2030
  • Figure 2-4: Canada - Breakup of Diabetes Patients* by Age Group (in 000' s), 2010, 2015, 2020, 2025 & 2030
  • Figure 2-5: Canada - Breakup of Diabetes Patients* by Age Group (in %) 2010, 2015, 2020, 2025 & 2030
  • Figure 3-1: Canada - Diabetes Market (in Million US$), 2005-2010
  • Figure 3-2: Canada - Diabetes Market - Breakup of Insulin and Oral Antidiabetics (in %), 2005-2010
  • Figure 3-3: Canada - Diabetes Market Forecast (in Million US$), 2011-2016
  • Figure 3-4: Canada - Diabetes Market - Breakup of Insulin and Oral Antidiabetics (in %), 2011-2016
  • Figure 3-5: Canada - Insulin Market (in Million US$), 2005-2010
  • Figure 3-6: Canada - Insulin Market - Share by Class (in %), 2005-2010
  • Figure 3-7: Canada - Insulin Market - Share by Molecules (in %), 2005-2010
  • Figure 3-8: Canada - Insulin Market - Share of Key Players (in %), 2005-2010
  • Figure 3-9: Canada - Insulin Market - Share of Key Drugs (in %), 2005-2010
  • Figure 3-10: Canada - Insulin Market Forecast (in Million US$), 2011-2016
  • Figure 3-11: Canada - Oral Antidiabetics Market, (in Million US$), 2005-2010
  • Figure 3-12: Canada - Oral Antidiabetics Market - Share by Class (in %), 2005-2010
  • Figure 3-13: Canada - Oral Antidiabetics Market - Share of Key Players (in %), 2005-2010
  • Figure 3-14: Canada - Oral Antidiabetics Market - Share of Key Drugs (in %), 2005-2010
  • Figure 3-15: Canada - Oral Antidiabetics Market Forecast (in Million US$), 2011-2016
  • Figure 3-16: Canada - Oral Antidiabetics Market - Share Forecast by Class (%), 2010-2016

List of Tables:

  • Table 1-1: Canada - Oral Antidiabetics & Insulin Market Definitions
  • Table 3-1: Canada - Insulin Market - Sales by Class (in Million US$), 2005-2010
  • Table 3-2: Canada - Insulin Market - Sales by Molecule (in Million US$), 2005-2010
  • Table 3-3: Canada - Insulin Market - Share of Key Players (in Million US$), 2005-2010
  • Table 3-4: Canada - Insulin Market - Sales of Key Drugs (in Million US$), 2005-2010
  • Table 3-5: Canada - Oral Antidiabetics Market - Sales by Class (in Million US$), 2005-2010
  • Table 3-6: Canada - Oral Antidiabetics Market - Sales of Key Players (in Million US$), 2005-2010
  • Table 3-7: Canada - Oral Antidiabetics Market - Sales of Key Drugs (in Million US$), 2005-2010
  • Table 3-9: Canada - Oral Antidiabetics - Sales Forecast by Class, (in Million US$), 2010, 2013 & 2016
  • Table 3-8: Canada - Oral Antidiabetics Market - New Drug Launches (2011-2016)
Back to Top